Compare BLLN & MIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLLN | MIR |
|---|---|---|
| Founded | 2016 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.9B |
| IPO Year | 2025 | 2020 |
| Metric | BLLN | MIR |
|---|---|---|
| Price | $104.82 | $16.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $126.71 | $27.25 |
| AVG Volume (30 Days) | 501.7K | ★ 3.2M |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 103.40 | ★ 161.11 |
| EPS | ★ 0.48 | 0.02 |
| Revenue | ★ $305,112,000.00 | N/A |
| Revenue This Year | $46.29 | $23.95 |
| Revenue Next Year | $30.14 | $7.32 |
| P/E Ratio | ★ $220.69 | $783.00 |
| Revenue Growth | ★ 99.97 | N/A |
| 52 Week Low | $61.96 | $14.11 |
| 52 Week High | $150.44 | $30.28 |
| Indicator | BLLN | MIR |
|---|---|---|
| Relative Strength Index (RSI) | 53.45 | 54.75 |
| Support Level | $79.07 | $15.60 |
| Resistance Level | $108.50 | $17.48 |
| Average True Range (ATR) | 5.08 | 0.66 |
| MACD | 1.86 | 0.04 |
| Stochastic Oscillator | 64.44 | 57.96 |
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
Mirion Technologies Inc provides products, services, and software that allow customers to safely leverage the power of ionizing radiation for applications that benefit the health, safety, vitality, and technological progress of the human experience. The Company manages its operations through two segments: Nuclear & Safety and Medical. The Medical segment improves the quality and safety of cancer care delivery and supports applications across medical diagnostics and practitioner safety. The Nuclear & Safety segment powers advancements in nuclear energy and critical radiation safety, measurement and analysis applications across laboratories, research and other industrial markets such as defense.